EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioNTech SE's enterprise value is $4,537 Mil.
BioNTech SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $1,189 Mil. Therefore, BioNTech SE's EV-to-EBITDA for today is 3.81.
The historical rank and industry rank for BioNTech SE's EV-to-EBITDA or its related term are showing as below:
BNTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -196.43 Med: 1.65 Max: 32.16
Current: 3.81
During the past 8 years, the highest EV-to-EBITDA of BioNTech SE was 32.16. The lowest was -196.43. And the median was 1.65.
BNTX's EV-to-EBITDA is ranked better than 59.52% of 462
companies
in the Biotechnology industry
Industry Median: 9.55
vs BNTX: 3.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
BioNTech SE EV-to-EBITDA Historical Data
The historical data trend for BioNTech SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNTech SE's EV-to-EBITDA
For the Biotechnology subindustry, BioNTech SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioNTech SE's EV-to-EBITDA falls into.
BioNTech SE EV-to-EBITDA Calculation
BioNTech SE's EV-to-EBITDA for today is calculated as:
BioNTech SE's current Enterprise Value is $4,537 Mil.
BioNTech SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,189 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (NAS:BNTX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BioNTech SE's PE Ratio for today is calculated as:
BioNTech SE's share price for today is $92.72.
BioNTech SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.115.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of BioNTech SE's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTX has been successfully added to your 